Biomediq A/S does R&D and implementation of quantitative imaging biomarkers for use in clinical trials and patient diagnosis, prognosis, screening, and monitoring. Automated analysis of scans provide quantitative markers. New markers are developed by machine learning technologies based on large databases of patient information. Markers are validated in clinical studies. Major therapeutic areas are osteoarthritis, rheumatoid arthritis, breast cancer, osteoporosis, cardiovascular disease, and Alzheimer's disease. Biomediq especially has developed and intellectually protected texture markers of breast cancer risk in mammograms based on supervised learning, and demonstrated that these consistently improve over breast density measurements alone for risk segregation.